X
XORTX Therapeutics Inc. (XRTX)
NCM – Real Time Price. Currency in USD
2.19
+0.03 (1.44%)
At close: Jun 26, 2026, 4:00 PM EDT
2.20
+0.01 (0.38%)
After-hours: Jun 26, 2026, 6:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.19
+0.03 (1.44%)
At close: Jun 26, 2026, 4:00 PM EDT
2.20
+0.01 (0.38%)
After-hours: Jun 26, 2026, 6:53 PM EDT
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
| Name | Position |
|---|---|
| Dr. Michael Scott Bumby D.V.M., M.B.A. | Chief Financial Officer |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-15 | 6-K | f6k_061526.htm |
| 2026-06-12 | 6-K | f6k_061226.htm |
| 2026-05-19 | 6-K | f6k_051826.htm |
| 2026-05-14 | 6-K | f6k_051426.htm |
| 2026-05-08 | POS AM | tm265452-8_posam.htm |
| 2026-05-08 | 6-K | tm265452d11_6k.htm |
| 2026-04-23 | POS AM | tm265452-6_posam.htm |
| 2026-04-22 | POS AM | tm265452-4_posam.htm |
| 2026-04-21 | 6-K | f6k_042126.htm |
| 2026-04-16 | 6-K | f6k_041626.htm |